Ani Pharmaceuticals (ANIP) Preferred Stock Liabilities (2021 - 2025)

Ani Pharmaceuticals has reported Preferred Stock Liabilities for 5 years, with the latest figure at $24.8 million in Q2 2025.

• Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $24.8 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $24.8 million (changed 0.0% YoY) and the FY2024 annual result came in at $24.8 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities was little changed at $24.8 million in Q2 2025 per ANIP's latest filing, from $24.8 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $24.8 million in Q4 2021 and troughed at $24.8 million in Q4 2021.
• A 5-year average of $24.8 million and a median of $24.8 million in 2021 frame the typical range for Preferred Stock Liabilities.
• The widest YoY moves for Preferred Stock Liabilities: up 0.0% in 2022, down 0.0% in 2022.
• Over 5 years, Preferred Stock Liabilities stood at $24.8 million in 2021, then changed by 0.0% to $24.8 million in 2022, then changed by 0.0% to $24.8 million in 2023, then changed by 0.0% to $24.8 million in 2024, then changed by 0.0% to $24.8 million in 2025.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $24.8 million, $24.8 million, and $24.8 million for Q2 2025, Q1 2025, and Q4 2024 respectively.